Iodine-131 is primarily used in nuclear medicine for both imaging and therapy of the thyroid gland. It is also used, to a lesser extent, in diagnosing other medical conditions.
Key Uses of Iodine-131:
-
Thyroid Imaging: Iodine-131 emits gamma rays that can be detected by a gamma camera, allowing doctors to visualize the thyroid gland's size, shape, and function. This helps diagnose conditions like goiters, nodules, and thyroiditis.
-
Treatment of Hyperthyroidism: In cases of hyperthyroidism (overactive thyroid), iodine-131 is administered orally. The thyroid gland absorbs the radioactive iodine, which then destroys overactive thyroid cells. This reduces thyroid hormone production and alleviates symptoms.
-
Treatment of Thyroid Cancer: After surgical removal of the thyroid gland in patients with thyroid cancer, iodine-131 is often used to destroy any remaining thyroid tissue (radioactive iodine ablation) and to treat thyroid cancer that has spread to other parts of the body (metastatic disease). The radioiodine targets and destroys thyroid cells, minimizing damage to other tissues.
-
Diagnosis of Other Conditions (Less Common): Although less frequently used, iodine-131 can also assist in the diagnosis of:
- Abnormal liver function
- Kidney blood flow issues (renal blood flow)
- Urinary tract obstructions
Why Iodine-131 is Effective:
The thyroid gland actively takes up iodine from the bloodstream to produce thyroid hormones. Because of this natural affinity, iodine-131 is selectively absorbed by thyroid tissue, allowing for targeted imaging and therapy. The beta radiation emitted by iodine-131 has a short range in tissue, limiting damage to surrounding structures when used therapeutically.
Summary:
Iodine-131 is a radioactive isotope of iodine widely employed in nuclear medicine for both diagnostic imaging and therapeutic treatment, particularly for conditions affecting the thyroid gland. While its primary applications lie in managing thyroid disorders, it also has limited use in diagnosing other medical conditions.
